The US FDA has granted accelerated approval of CSL Behring's clotting agent RiaSTAP (fibrinogen concentrate (human)) for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, an orphan indication that affects 150-300 people in the US.
The biological is indicated for patients with afibrogenaemia (absence or very low levels of plasma fibrinogen) and hypofibrinogaenemia (levels below...